138 related articles for article (PubMed ID: 24954766)
1. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.
Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
Eur J Haematol; 2015 Jan; 94(1):60-6. PubMed ID: 24954766
[TBL] [Abstract][Full Text] [Related]
2. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies.
Ostrovsky O; Korostishevsky M; Levite I; Leiba M; Galski H; Vlodavsky I; Nagler A
Leukemia; 2007 Nov; 21(11):2296-303. PubMed ID: 17611567
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
4. Association of heparanase gene (HPSE-1) single nucleotide polymorphisms with gastric cancer.
Yue Z; Song Y; Wang Z; Luo Y; Jiang L; Xing L; Xu H; Zhang X
J Surg Oncol; 2010 Jul; 102(1):68-72. PubMed ID: 20578081
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.
Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
Int J Cancer; 2012 Sep; 131(5):E636-42. PubMed ID: 22139971
[TBL] [Abstract][Full Text] [Related]
6. Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma.
Ostrovsky O; Beider K; Magen H; Leiba M; Sanderson RD; Vlodavsky I; Nagler A
Cells; 2023 Mar; 12(6):. PubMed ID: 36980254
[TBL] [Abstract][Full Text] [Related]
7. Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation.
Ostrovsky O; Korostishevsky M; Shafat I; Mayorov M; Ilan N; Vlodavsky I; Nagler A
J Leukoc Biol; 2009 Aug; 86(2):445-55. PubMed ID: 19406828
[TBL] [Abstract][Full Text] [Related]
8. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M; Sevcikova S; Slaby O; Kaisarova P; Maisnar V; Penka M; Pika T; Pour L; Radocha J; Scudla V; Svachova H; Hajek R
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):414-20. PubMed ID: 21859556
[TBL] [Abstract][Full Text] [Related]
9. The CXCL12-3'A allele plays a favourable role in patients with multiple myeloma.
Mazur G; Gębura K; Gieryng A; Butrym A; Wróbel T; Bogunia-Kubik K
Cytokine; 2013 Oct; 64(1):422-6. PubMed ID: 23711392
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
11. The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.
Bachmann HS; Novotny J; Sixt S; Liebisch P; Frey UH; Dührsen U; Siffert W; Nückel H
Eur J Haematol; 2010 Aug; 85(2):108-13. PubMed ID: 20408869
[TBL] [Abstract][Full Text] [Related]
12. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.
Vangsted AJ; Klausen TW; Ruminski W; Gimsing P; Andersen NF; Gang AO; Abildgaard N; Knudsen LM; Nielsen JL; Gregersen H; Vogel U
Bone Marrow Transplant; 2009 Apr; 43(7):539-45. PubMed ID: 18997828
[TBL] [Abstract][Full Text] [Related]
13. C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease.
Sonmez M; Kazaz N; Yucel B; Topbas M; Ucar F
Hematology; 2014 Jun; 19(4):213-6. PubMed ID: 24074513
[TBL] [Abstract][Full Text] [Related]
14. Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.
Ralph S; Brenchley PE; Summers A; Rosa DD; Swindell R; Jayson GC
Cancer Sci; 2007 Jun; 98(6):844-9. PubMed ID: 17419711
[TBL] [Abstract][Full Text] [Related]
15. MDR1 polymorphism influences the outcome of multiple myeloma patients.
Buda G; Maggini V; Galimberti S; Martino A; Giuliani N; Morabito F; Genestreti G; Iacopino P; Rizzoli V; Barale R; Rossi AM; Petrini M
Br J Haematol; 2007 Jun; 137(5):454-6. PubMed ID: 17488488
[TBL] [Abstract][Full Text] [Related]
16. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.
de Larrea CF; Navarro A; Tejero R; Tovar N; Díaz T; Cibeira MT; Rosiñol L; Ferrer G; Rovira M; Rozman M; Monzó M; Bladé J
Clin Cancer Res; 2012 Jul; 18(13):3697-704. PubMed ID: 22539802
[TBL] [Abstract][Full Text] [Related]
17. Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.
Varga G; Mikala G; Kiss KP; Kosóczki É; Szabó E; Meggyesi N; Balassa K; Kövy P; Tegze B; Szombath G; Tordai A; Andrikovics H; Homolya L; Masszi T
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):734-742. PubMed ID: 28733196
[TBL] [Abstract][Full Text] [Related]
18.
Wróbel T; Butrym A; Łacina P; Rybka J; Gębura K; Mazur G; Bogunia-Kubik K
Anticancer Res; 2017 Apr; 37(4):1799-1803. PubMed ID: 28373444
[TBL] [Abstract][Full Text] [Related]
19. A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.
Vangsted AJ; Klausen TW; Gimsing P; Andersen NF; Abildgaard N; Gregersen H; Vogel U
Haematologica; 2009 Sep; 94(9):1274-81. PubMed ID: 19734419
[TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
